A Study of Inotuzumab and Blinatumomab in People With B-cell Acute Lymphoblastic Leukemia | MicrobiomeTrials← Back to trialsNCT07313852
A Study of Inotuzumab and Blinatumomab in People With B-cell Acute Lymphoblastic Leukemia
RecruitingPHASE1, PHASE2INTERVENTIONAL
Trial Details
Start: 2026-06Est. Completion: 2029-01
Enrollment target: 26 participants Locations- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York, New York, United States
Other microbiome trials you might be interested in
Macrophage Activation SyndromePrimary Hemophagocytic Lymphohistiocytosis
Immunotherapy is changing the landscape of cancer therapy. Particularly unique to immunotherapy is the toxicity profile,…
Bethesda, United StatesEst. completion Dec 31, 2026
Acute Lymphoblastic Leukemia in RemissionAcute Myeloid Leukemia Arising From Previous Myelodysplastic SyndromeAcute Myeloid Leukemia in RemissionChronic Myelomonocytic LeukemiaMyelodysplastic Syndrome With Excess Blasts
Recurrent Acute Lymphoblastic Leukemia
Recurrent Acute Myeloid Leukemia
Refractory Acute Lymphoblastic Leukemia
Refractory Acute Myeloid Leukemia
Recurrent Mixed Phenotype Acute Leukemia
Refractory Mixed Phenotype Acute Leukemia
Hematopoietic and Lymphoid Cell Neoplasm
This phase I/II trial studies the side effects and best dose of a radioactive agent linked to an antibody (211At-BC8-B10…
Seattle, United StatesEst. completion Jan 28, 2028